|1.||Cassella, James V: 6 articles (12/2014 - 01/2011)|
|2.||Spyker, Daniel A: 5 articles (12/2014 - 01/2011)|
|3.||Allen, Michael H: 4 articles (11/2013 - 01/2011)|
|4.||Fishman, Robert S: 3 articles (12/2014 - 02/2012)|
|5.||Hellings, Jessica A: 2 articles (10/2015 - 03/2015)|
|6.||Lachaux, B: 2 articles (09/2012 - 07/2006)|
|7.||Citrome, L: 2 articles (03/2012 - 03/2011)|
|8.||Riesenberg, Robert A: 2 articles (02/2012 - 01/2011)|
|9.||Kehne, John H: 2 articles (02/2012 - 01/2011)|
|10.||Feifel, David: 2 articles (10/2011 - 01/2011)|
|1.||Schizophrenia (Dementia Praecox)
02/01/2012 - "Two national pharmacoepidemiological studies were conducted in France, a retrospective survey RÉALITÉ and a prospective study RÉALITÉ LT, to examine the use of loxapine, first in acute and chronic psychotic states and second in long-term treatment prescribed for patients with schizophrenia. "
02/01/2012 - "[RÉALITÉ LT, a pharmacoepidemiological study of semiology and therapeutic strategy of patients with schizophrenia treated by antipsychotic loxapine in routine clinical practice]."
10/01/2011 - "Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial."
01/01/2011 - "Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine."
01/01/2007 - "We included all randomised controlled clinical trials relevant to the care of schizophrenia that compared loxapine to other treatments. "
|2.||Bipolar Disorder (Mania)
02/01/2012 - "Agitated patients (N=314) with bipolar I disorder (manic or mixed episodes) were randomized (1:1:1) to inhaled loxapine 5 mg or 10 mg, or inhaled placebo using the Staccato® system. "
03/01/2013 - "Inhaled loxapine: a new treatment for agitation in schizophrenia or bipolar disorder."
03/01/2012 - "To describe the efficacy of inhaled loxapine for the treatment of agitation associated with schizophrenia or bipolar disorder using different examples of effect size (ES). "
01/01/2013 - "Administered via a single-use device, inhaled loxapine was tested in randomized controlled trials in agitation associated with schizophrenia or bipolar mania; doses of 5 mg and 10 mg were found to be efficacious, with an apparent dose response. "
03/01/2012 - "Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder."
|3.||Psychotic Disorders (Schizoaffective Disorder)
10/01/2011 - "Inhaled loxapine was generally safe and well tolerated and produced rapid improvement in agitated patients with psychotic disorders. "
09/01/2014 - "[Inhaled loxapine: A novel treatment for agitation in psychotic disorders]."
10/01/2011 - "The objective of this study was to assess the efficacy and safety of inhaled loxapine in the treatment of agitation in patients with psychotic disorders. "
11/01/1997 - "The purpose of this study was to document loxapine's 5-HT2 and D2 receptor occupancy in vivo in patients with psychoses. "
04/01/1993 - "Loxapine is a drug which is used in the treatment of psychotic disorders. "
|4.||Depressive Disorder (Melancholia)
02/01/1976 - "Within a duration of treatment of 3 and 4 weeks desmethyl-loxapine [CL 67 772, 2-chloro-11-(1-piperazinyl)-dibenz (b,f)(1,4)-oxazepine] was tested in an open study as an antidepressant on 16 patients with different depressive syndromes. "
08/01/1983 - "Loxapine in the treatment of psychotic-depressive disorders: Measurement of antidepressant metabolites."
08/01/1983 - "The results demonstrate that many patients treated with loxapine attain substantial serum levels of total amoxapine, some in concentrations thought to be therapeutic for nonpsychotic endogenous depression. "
09/01/1982 - "This study compared the therapeutic efficacy of thioridazine, loxapine, and a placebo in the treatment of behavioral disturbances in nursing home patients with dementia. "
06/01/1998 - "The neuroleptic-induced dementia occurred while the individuals were on a low dose of either loxapine, thioridazine, haloperidol, or pimozide."
|1.||Antipsychotic Agents (Antipsychotics)
|6.||Dopamine Receptors (Dopamine Receptor)
|10.||Succinic Acid (Succinate)
|1.||Home Nursing (Nursing, Home)
|2.||Nebulizers and Vaporizers (Inhaler)